Dr. Brendan Bauer is a neurologist in Bellevue, Ohio and is affiliated with multiple hospitals in the area, including Bellevue Hospital and Fisher-Titus Medical Center. He received his medical degree from University of Toledo College of Medicine and has been in practice between 11-20 years.
Dr. Denis Gris has started his scientific career with the Master's and Ph.D. in Neuroscience at Dr. Lynn Weaver's laboratory at the University of Western Ontario. He studied the role of inflammation in spinal cord injury. He discovered that the influx of neutrophils is detrimental for recovering after spinal cord injury. Using anti CD11d antibody as a treatment, he demonstrated that animals recovered faster and better after the treatment. Also, he showed that sever spinal cord injury results in massive inflammatory reactions throughout the body leading to syndrome similar to multiple organ dysfunction syndrome. Dr. Denis Gris continued his education in Dr. Jenny P-Y Ting's laboratory as a post doctoral fellow at the University of North Carolina at Chapel Hill. There he studied in detail mechanism of activation of innate and adoptive immune responses. In collaboration with Dr. Wen, Dr. Eitas, Dr. Allen, and other members of the laboratory, Dr. Gris studied inflammation during obesity which leads to insulin resistance; innate and adoptive responses during multiple sclerosis. In summary, his role in this laboratory was to define the role of novel family of immuno regulatory proteins (NLRs) in different human diseases. Currently, Dr. Denis Gris is a member of Immunology Program at the University of Sherbrooke and he is studying neuro-immune interactions during healthy state and disease.
Behavioral neuroscience, Neuro-immunology, and Autoimmune Diseases
Presently: Director, Co-Founder of SignPath Pharma, developing Curcumin for treatment of cancer. Founder, Chairman & CEO of VITRUVIAN BioMedical, Inc. which is developing an Alzheimer Disease Blood Test and Therapeutic Vaccine. First company founded was Wadley Biosciences/LPL which was a joint venture between Wadley Institutes and Phillips Petroleum with focus on cancer and infectious disease, 1987-1992. The second company founded was Cytoclonal Pharmaceutics, which went public with an IPO in 1995, and entered into a licensing agreement with Bristol Myers on Taxol production, and was merged to create OPKO Health. Former Chairman & CEO of HemoBioTech, Inc., developing HemoTech as viable substitute for human red blood cells.
Neurology, Neuro-degenerative diseases